The latest scientific articles on TAVI published on our website

01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Read also HERE 02-<a href="https://solaci.org/en/2021/10/05/the-latest-scientific-articles-on-tavi-published-on-our-website/" title="Read more" >...</a>

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>

SOLACI-CACI 2021 | SAC-FAC Session

✔️ Watch again the complete SAC-FAC Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: – SESSION I: Functional Mitral Regurgitation: New Horizons for Transcatheter Therapy 01:06 – Optimal Medical Treatment in Patients with Cardiac Failure and Mitral Regurgitation – Florencia Renedo 12:12 – Ultrasonographic Screening of Patients for Endovascular Therapy – Walter García 25:43 –<a href="https://solaci.org/en/2021/09/14/solaci-caci-2021-sac-fac-session-2/" title="Read more" >...</a>

ESC 2021 | Novedades de las nuevas guías de valvulopatías de la Sociedad Europea de Cardiología

ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease

Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European Society of Cardiology (ESC) Guidelines for the Management of Valvular Heart Disease.  This new document was<a href="https://solaci.org/en/2021/09/09/esc-2021-updated-european-society-of-cardiology-guidelines-for-the-management-of-valvular-heart-disease/" title="Read more" >...</a>

SOLACI-CACI 2021 | International Sessions with the Most Renowned Societies Worldwide

  INTERNATIONAL SESSIONS WITH THE MOST RENOWNED SOCIETIES WORLDWIDE Appealing sessions on the most relevant current topics in interventional cardiology will be at the forefront of a virtual, interactive event you do not want to miss! Save the date: August 2-6, 2021 Register now for FREE Learn more about the international joint sessions featured in<a href="https://solaci.org/en/2021/07/23/solaci-caci-2021-international-sessions-with-the-most-renowned-societies-worldwide/" title="Read more" >...</a>

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. However, surgeons argue that these cases fail to consider patients from daily clinical practice, but rather include a population that has been carefully selected for randomized trials. Patients with non-tricuspid aortic stenosis, with severe<a href="https://solaci.org/en/2021/03/25/surgeons-claim-on-low-risk-patients-with-aortic-stenosis/" title="Read more" >...</a>

The Ten Commandments in Adult Congenital Heart Disease

Adult congenital heart disease is a life-long condition that requires appropriate follow-up by experts. Said follow-up is paramount to diagnosing specific and highly variable complications in a timely manner. The recently published European Society of Cardiology guidelines for the management of congenital heart disease calls for a summary of its most important aspects as “ten<a href="https://solaci.org/en/2020/12/15/the-ten-commandments-in-adult-congenital-heart-disease/" title="Read more" >...</a>

El estudio SOURCE 3 confirma los buenos resultados de la válvula SAPIEN 3 a un año de seguimiento

SAPIEN 3: Good Outcomes in Bicuspids

Courtesy of Dr. Carlos Fava. Bicuspid aortic valves are found in approximately 2% of patients and represent the most frequent cause of aortic stenosis in young adults requiring valve replacement. Though TAVR has advanced significantly, this entity has not yet been included in the different randomized studies. At present, we have data from different reports,<a href="https://solaci.org/en/2020/08/21/sapien-3-good-outcomes-in-bicuspids/" title="Read more" >...</a>

The Most Read Scientific Articles of March

01- Coronavirus and the Heart: How Should Cardiologists Prepare? As the number of confirmed cases increases throughout the globe, a picture is emerging as to what the direct cardiovascular effects of this pandemic may be. Read more HERE 02- TAVR: Should Transradial Approach be the Second Access Site? Courtesy of Dr. Carlos Fava. One of<a href="https://solaci.org/en/2020/04/08/the-most-read-scientific-articles-of-march/" title="Read more" >...</a>

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

PASCAL in Tricuspid Regurgitation with Encouraging Results

Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is associated with higher mortality and morbidity, and it most frequently has a functional cause. Furthermore, it has been proven that tricuspid surgery has mortality rates between 8% and 20%. On the other hand, it has been verified that, in the case of left-sided disease affecting the<a href="https://solaci.org/en/2020/01/21/pascal-in-tricuspid-regurgitation-with-encouraging-results/" title="Read more" >...</a>

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

transcatheter mitral valve